NASDAQ:CKPT - Checkpoint Therapeutics Stock Price, Price Target & More

$3.97 -0.15 (-3.64 %)
(As of 04/24/2018 06:18 AM ET)
Previous Close$4.12
Today's Range$3.95 - $4.11
52-Week Range$3.20 - $13.00
Volume36,700 shs
Average Volume76,642 shs
Market Capitalization$131.90 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Checkpoint Therapeutics (NASDAQ:CKPT)

Checkpoint Therapeutics logoCheckpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. Its pipeline consists of human, immuno-oncology, and checkpoint inhibitor antibodies that target programmed death-ligand 1; glucocorticoid-induced TNFR-related protein; and carbonic anhydrase IX. The company is also developing three oral, small-molecule, targeted anti-cancer agents that inhibit epidermal growth-factor receptor mutations, the bromodomain and extra-terminal protein BRD4, and poly polymerase. Checkpoint Therapeutics, Inc. has a collaboration agreement with TG Therapeutics, Inc. to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Receive CKPT News and Ratings via Email

Sign-up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CKPT
CUSIPN/A
Phone781-652-4500

Debt

Debt-to-Equity RatioN/A
Current Ratio3.36%
Quick Ratio3.36%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.73 million
Price / Sales73.46
Cash FlowN/A
Price / CashN/A
Book Value$0.59 per share
Price / Book6.73

Profitability

EPS (Most Recent Fiscal Year)($1.00)
Net Income$-22,670,000.00
Net Margins-1,316.72%
Return on Equity-102.39%
Return on Assets-83.05%

Miscellaneous

Employees6
Outstanding Shares32,010,000

How to Become a New Pot Stock Millionaire

Checkpoint Therapeutics (NASDAQ:CKPT) Frequently Asked Questions

What is Checkpoint Therapeutics' stock symbol?

Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT."

How were Checkpoint Therapeutics' earnings last quarter?

Checkpoint Therapeutics (NASDAQ:CKPT) posted its earnings results on Friday, March, 16th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.01. The company earned $0.33 million during the quarter, compared to the consensus estimate of $0.35 million. Checkpoint Therapeutics had a negative net margin of 1,316.72% and a negative return on equity of 102.39%. View Checkpoint Therapeutics' Earnings History.

What price target have analysts set for CKPT?

1 brokers have issued 1 year target prices for Checkpoint Therapeutics' stock. Their predictions range from $11.00 to $11.00. On average, they expect Checkpoint Therapeutics' stock price to reach $11.00 in the next year. View Analyst Ratings for Checkpoint Therapeutics.

Who are some of Checkpoint Therapeutics' key competitors?

Who are Checkpoint Therapeutics' key executives?

Checkpoint Therapeutics' management team includes the folowing people:
  • Mr. Michael S. Weiss, Exec. Chairman (Age 52)
  • Mr. James F. Oliviero III, CFA, Chief Exec. Officer and Pres (Age 42)
  • Mr. William Garrett Gray, Principal Financial Officer and VP of Fin. & Accounting (Age 31)
  • Ms. Robyn M. Hunter, Corp. Sec.

Has Checkpoint Therapeutics been receiving favorable news coverage?

News articles about CKPT stock have been trending somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Checkpoint Therapeutics earned a news sentiment score of 0.24 on Accern's scale. They also gave media headlines about the company an impact score of 46.60 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Checkpoint Therapeutics?

Shares of CKPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Checkpoint Therapeutics' stock price today?

One share of CKPT stock can currently be purchased for approximately $3.97.

How big of a company is Checkpoint Therapeutics?

Checkpoint Therapeutics has a market capitalization of $131.90 million and generates $1.73 million in revenue each year. The company earns $-22,670,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Checkpoint Therapeutics employs 6 workers across the globe.

How can I contact Checkpoint Therapeutics?

Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]


MarketBeat Community Rating for Checkpoint Therapeutics (CKPT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  63 (Vote Outperform)
Underperform Votes:  49 (Vote Underperform)
Total Votes:  112
MarketBeat's community ratings are surveys of what our community members think about Checkpoint Therapeutics and other stocks. Vote "Outperform" if you believe CKPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CKPT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Checkpoint Therapeutics (NASDAQ:CKPT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Checkpoint Therapeutics in the last 12 months. Their average twelve-month price target is $11.00, suggesting that the stock has a possible upside of 177.08%. The high price target for CKPT is $11.00 and the low price target for CKPT is $11.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.00$11.00$11.00N/A
Price Target Upside: 177.08% upside138.61% upside138.61% upsideN/A

Checkpoint Therapeutics (NASDAQ:CKPT) Consensus Price Target History

Price Target History for Checkpoint Therapeutics (NASDAQ:CKPT)

Checkpoint Therapeutics (NASDAQ:CKPT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/8/2017HC WainwrightInitiated CoverageBuy -> Buy$11.00HighView Rating Details
3/22/2017Ladenburg ThalmannInitiated CoverageBuyLowView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Checkpoint Therapeutics (NASDAQ:CKPT) Earnings History and Estimates Chart

Earnings by Quarter for Checkpoint Therapeutics (NASDAQ:CKPT)

Checkpoint Therapeutics (NASDAQ:CKPT) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.84 EPS
Next Year EPS Consensus Estimate: $-0.99 EPS

Checkpoint Therapeutics (NASDAQ CKPT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/16/2018Q4 2017($0.27)($0.26)$0.35 million$0.33 millionViewN/AView Earnings Details
11/3/2017Q3 2017($0.26)$0.35 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.28)$0.35 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Checkpoint Therapeutics (NASDAQ:CKPT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Checkpoint Therapeutics (NASDAQ CKPT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.70%
Institutional Ownership Percentage: 0.56%
Insider Trading History for Checkpoint Therapeutics (NASDAQ:CKPT)

Checkpoint Therapeutics (NASDAQ CKPT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Checkpoint Therapeutics (NASDAQ CKPT) News Headlines

Source:
DateHeadline
Checkpoint Therapeutics (CKPT) Reports Preclinical Data on BET Inhibitor CK-103 at AACRCheckpoint Therapeutics (CKPT) Reports Preclinical Data on BET Inhibitor CK-103 at AACR
www.streetinsider.com - April 19 at 9:41 AM
Checkpoint Therapeutics Reports Preclinical Data on BET Inhibitor CK-103 at the American Association for Cancer Research Annual MeetingCheckpoint Therapeutics Reports Preclinical Data on BET Inhibitor CK-103 at the American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 18 at 9:40 AM
Zacks Investment Research Upgrades Checkpoint Therapeutics (CKPT) to "Buy"Zacks Investment Research Upgrades Checkpoint Therapeutics (CKPT) to "Buy"
www.americanbankingnews.com - April 10 at 2:51 PM
Zacks: Checkpoint Therapeutics (CKPT) Given Average Recommendation of "Strong Buy" by BrokeragesZacks: Checkpoint Therapeutics (CKPT) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - April 9 at 5:23 AM
Zacks Investment Research Downgrades Checkpoint Therapeutics (CKPT) to HoldZacks Investment Research Downgrades Checkpoint Therapeutics (CKPT) to Hold
www.americanbankingnews.com - April 6 at 8:10 PM
Why Checkpoint Therapeutics (CKPT) Might Be a Diamond in the RoughWhy Checkpoint Therapeutics (CKPT) Might Be a Diamond in the Rough
www.zacks.com - April 5 at 8:48 AM
Checkpoint Therapeutics (CKPT) Downgraded by Zacks Investment Research to HoldCheckpoint Therapeutics (CKPT) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 30 at 8:23 PM
Checkpoint Therapeutics (CKPT) Upgraded to "Buy" at Zacks Investment ResearchCheckpoint Therapeutics (CKPT) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 7:58 PM
Checkpoint Therapeutics (CKPT) Presents At The Wall Street Investor Forum 26th Annual Growth Conference - SlideshowCheckpoint Therapeutics (CKPT) Presents At The Wall Street Investor Forum 26th Annual Growth Conference - Slideshow
seekingalpha.com - March 26 at 4:11 PM
 Checkpoint Therapeutics Inc (CKPT) Given $15.50 Average Target Price by Brokerages Checkpoint Therapeutics Inc (CKPT) Given $15.50 Average Target Price by Brokerages
www.americanbankingnews.com - March 25 at 8:56 AM
Checkpoint Therapeutics (CKPT) Upgraded by Zacks Investment Research to "Buy"Checkpoint Therapeutics (CKPT) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - March 21 at 8:22 PM
Brokerages Expect Checkpoint Therapeutics Inc (CKPT) to Post ($0.19) Earnings Per ShareBrokerages Expect Checkpoint Therapeutics Inc (CKPT) to Post ($0.19) Earnings Per Share
www.americanbankingnews.com - March 21 at 3:14 AM
Blog Exposure - Checkpoint Therapeutics to Present Preclinical Data on its BET Inhibitor CK-103 at AACR MeetingBlog Exposure - Checkpoint Therapeutics to Present Preclinical Data on its BET Inhibitor CK-103 at AACR Meeting
finance.yahoo.com - March 19 at 9:50 AM
CHECKPOINT THERAPEUTICS beats by $0.05, beats on revenueCHECKPOINT THERAPEUTICS beats by $0.05, beats on revenue
seekingalpha.com - March 17 at 4:53 PM
Checkpoint Therapeutics Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research Annual MeetingCheckpoint Therapeutics Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research Annual Meeting
finance.yahoo.com - March 15 at 9:36 AM
Checkpoint Therapeutics to Participate in March Investor ConferencesCheckpoint Therapeutics to Participate in March Investor Conferences
finance.yahoo.com - March 13 at 10:02 AM
Checkpoint Therapeutics prices stock offering at $4.35; shares down 17% premarketCheckpoint Therapeutics prices stock offering at $4.35; shares down 17% premarket
seekingalpha.com - March 8 at 5:06 PM
Zacks: Analysts Set $15.50 Price Target for Checkpoint Therapeutics Inc (CKPT)Zacks: Analysts Set $15.50 Price Target for Checkpoint Therapeutics Inc (CKPT)
www.americanbankingnews.com - March 6 at 11:51 AM
 Checkpoint Therapeutics Inc (CKPT) Receives Average Rating of "Strong Buy" from Analysts Checkpoint Therapeutics Inc (CKPT) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - February 27 at 1:44 PM
Zacks: Checkpoint Therapeutics Inc (CKPT) Receives Consensus Rating of "Strong Buy" from BrokeragesZacks: Checkpoint Therapeutics Inc (CKPT) Receives Consensus Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - February 12 at 3:34 AM
BRIEF-Argos Obtains Option To License PD1 Checkpoint InhibitorsBRIEF-Argos Obtains Option To License PD1 Checkpoint Inhibitors
www.reuters.com - February 6 at 4:33 PM
Checkpoint Therapeutics to Present at BIO CEO & Investor ConferenceCheckpoint Therapeutics to Present at BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 9:00 AM
 Checkpoint Therapeutics Inc (CKPT) Given Average Rating of "Strong Buy" by Brokerages Checkpoint Therapeutics Inc (CKPT) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - February 3 at 7:38 PM
 Checkpoint Therapeutics Inc (CKPT) Given Average Recommendation of "Strong Buy" by Brokerages Checkpoint Therapeutics Inc (CKPT) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 25 at 3:30 PM
Checkpoint Therapeutics (CKPT) vs. The Competition Financial AnalysisCheckpoint Therapeutics (CKPT) vs. The Competition Financial Analysis
www.americanbankingnews.com - January 24 at 9:28 PM
Analyzing Checkpoint Therapeutics (CKPT) and The CompetitionAnalyzing Checkpoint Therapeutics (CKPT) and The Competition
www.americanbankingnews.com - January 23 at 3:12 PM
Checkpoint Therapeutics (CKPT) Cut to "Hold" at Zacks Investment ResearchCheckpoint Therapeutics (CKPT) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 22 at 9:18 PM
Checkpoint Therapeutics (CKPT) Rating Increased to Buy at Zacks Investment ResearchCheckpoint Therapeutics (CKPT) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - January 19 at 8:44 PM
Zacks Investment Research Lowers Checkpoint Therapeutics (CKPT) to HoldZacks Investment Research Lowers Checkpoint Therapeutics (CKPT) to Hold
www.americanbankingnews.com - January 10 at 7:46 PM
 Checkpoint Therapeutics Inc (CKPT) Given $15.50 Consensus Target Price by Brokerages Checkpoint Therapeutics Inc (CKPT) Given $15.50 Consensus Target Price by Brokerages
www.americanbankingnews.com - January 9 at 7:58 AM
Checkpoint Therapeutics (CKPT) Lowered to "Hold" at Zacks Investment ResearchCheckpoint Therapeutics (CKPT) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 3 at 8:40 PM
Checkpoint Therapeutics to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018Checkpoint Therapeutics to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018
finance.yahoo.com - December 14 at 9:01 AM
Pionyr Immunotherapeutics Completes $62 Million Series B Financing to Advance Antibody-based Therapeutics Targeting the Tumor MicroenvironmentPionyr Immunotherapeutics Completes $62 Million Series B Financing to Advance Antibody-based Therapeutics Targeting the Tumor Microenvironment
www.bizjournals.com - December 13 at 9:10 AM
Checkpoint Therapeutics (CKPT) Receives New Coverage from Analysts at HC WainwrightCheckpoint Therapeutics (CKPT) Receives New Coverage from Analysts at HC Wainwright
www.americanbankingnews.com - December 8 at 11:50 PM
Immune Checkpoint Inhibitors Market to Collect Revenues US$ 30,000 Mn by 2026 End - Persistence Market ResearchImmune Checkpoint Inhibitors Market to Collect Revenues US$ 30,000 Mn by 2026 End - Persistence Market Research
www.bizjournals.com - November 27 at 6:16 PM
Zacks Investment Research Upgrades Checkpoint Therapeutics, Inc. (CKPT) to "Buy"Zacks Investment Research Upgrades Checkpoint Therapeutics, Inc. (CKPT) to "Buy"
www.americanbankingnews.com - November 23 at 5:58 PM
Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional SharesMirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
www.bizjournals.com - November 20 at 6:19 PM
Mirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And KRAS Inhibitor ProgramsMirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And KRAS Inhibitor Programs
www.thestreet.com - November 13 at 10:44 PM
Mirati Therapeutics Mocetinostat Included In Stand Up To Cancers Cutting-Edge Clinical Trial Initiative For NSCLC PatientsMirati Therapeutics' Mocetinostat Included In Stand Up To Cancer's Cutting-Edge Clinical Trial Initiative For NSCLC Patients
www.bizjournals.com - October 12 at 6:03 PM
Five Prime Therapeutics (FPRX) Says Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral Presentation at SITCFive Prime Therapeutics (FPRX) Says Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral Presentation at SITC
www.streetinsider.com - October 11 at 11:48 PM
BRIEF-Checkpoint Therapeutics initiates phase 1 study of antibody CK-301 for metastatic cancersBRIEF-Checkpoint Therapeutics initiates phase 1 study of antibody CK-301 for metastatic cancers
www.reuters.com - October 6 at 5:30 PM
Checkpoint Therapeutics (CKPT) Starts CK-301 TrialsCheckpoint Therapeutics (CKPT) Starts CK-301 Trials
finance.yahoo.com - October 5 at 11:21 AM
Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2017 Healthcare ConferenceCheckpoint Therapeutics to Present at the Ladenburg Thalmann 2017 Healthcare Conference
finance.yahoo.com - September 20 at 6:02 PM
Leap Therapeutics To Present At The 2017 Ladenburg Thalmann Healthcare ConferenceLeap Therapeutics To Present At The 2017 Ladenburg Thalmann Healthcare Conference
www.thestreet.com - September 19 at 10:15 PM
Mirati Therapeutics stock soars on heavy volume after positive cancer treatment trial resultsMirati Therapeutics' stock soars on heavy volume after positive cancer treatment trial results
www.marketwatch.com - September 15 at 10:40 PM
Mirati Therapeutics Presents Positive Preliminary Data From On-Going Clinical Trials Of Sitravatinib In Non-Small Cell Lung CancerMirati Therapeutics Presents Positive Preliminary Data From On-Going Clinical Trials Of Sitravatinib In Non-Small Cell Lung Cancer
www.bizjournals.com - September 14 at 5:59 PM
Checkpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive Non-Small Cell Lung CancerCheckpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer
finance.yahoo.com - September 11 at 5:55 PM
Checkpoint Therapeutics to Present at the 19th Annual Rodman & Renshaw Global Investment ConferenceCheckpoint Therapeutics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
finance.yahoo.com - September 5 at 6:47 PM

SEC Filings

Checkpoint Therapeutics (NASDAQ:CKPT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Checkpoint Therapeutics (NASDAQ CKPT) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.